Macrolide Antibiotic Market Size, Share & Industry Analysis, By Drug (Erythromycin, Azithromycin, Clarithromycin, and Others), By Indication (Respiratory Infections, Skin Infections, Sexually Transmitted Diseases (STDs), and Others,), By Route of Administration (Oral and Parenteral), By Age Group (Adults and Pediatric), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The macrolide antibiotic market is growing rapidly. Macrolides belong to the class of polyketides that are naturally occurring and exhibit antibiotic properties, thus appealing to their pharmaceutical applications. They consist of a group of glycosylated macrocyclic compounds formed by the chain extension of propionates cyclized into a large (typically 12, 14, or 16)-membered lactone ring with deoxy sugars. Macrolide antibiotics inhibit protein synthesis by reversibly binding to the 50S unit of the 70S ribosome of bacteria. They bind to the exit tunnel and partially clog it; they are often referred to as “tunnel plugs”. 

The newer generation of macrolides exhibits greater advantages, including increased bioavailability, longer half-life, and reduced impact of adverse effects. The development of resistance to the newer generation macrolides is also difficult.

• For instance, in July 2024, UIC Today reported that in a paper in Nature Chemical Biology, researchers studied different pathways to disrupt the bacterial cell function. Experiments conducted by these researchers concluded that the bacterial cell function can be disrupted not only by inhibiting protein synthesis but also by corrupting its DNA structure. 

The most widely used macrolides consist of azithromycin, clarithromycin, which are derived from erythromycin (first generation). The World Health Organization (WHO) has categorized macrolides as the Highest Priority Critically Important Antimicrobial (HPCIA) agents, considering their alternative therapies in medicine and their use. Macrolides currently share the HPCIA listing with quinolones, third-and-higher generation cephalosporins, glycopeptides, and polymyxins. Macrolides are one of the few available therapies for serious Campylobacter infections in humans, particularly in children who are not recommended to be treated with fluoroquinolones. 

Macrolides Antibiotic Market Driver

Need for Strong Macrolide Antibiotic Combating Drug-Resistant Infections Will Drive Market Growth

There have been rising concerns about the development of antibiotic-resistant microorganisms, posing a serious threat. Antimicrobial-resistant strains are estimated to have caused the deaths of 1.27 million people in 2019. To combat these infections, the need for strong macrolides will drive the market growth.

• For instance, according to the report by the World Economic Forum in October 2024, more than 50 million deaths could be prevented by increasing access to effective antibiotics. Various government initiatives are expected to support the cause.

Macrolides Antibiotic Market Restraint

Administration of Macrolide Antibiotics Increases Risk of Cardiovascular Conditions

There have been studies conducted that suggest that the utilization of stronger macrolides increases the risk of myocardial infarction. Other such complications that may arise due to drug interaction could hamper the market growth.

• For instance, according to research published in February 2023 in the journal Frontiers in Cardiovascular Medicine, reported that there was a risk associated with the administration of macrolide antibiotics. Administration of macrolide antibiotics increased the risk of sudden cardiac death (SCD) and cardiovascular death.

Macrolides Antibiotic Market Opportunity

Fast Track Approvals May Pose Significant Growth Opportunity

One of the major factors contributing to the market opportunity is the increasing demand for macrolide antibiotics. This has resulted in many macrolide antibiotic clinical trials and approvals on a fast-track basis. Companies are investing heavily in their research and development initiatives for the development of macrolide antibiotics.

• For instance, in January 2025, Wockhardt Ltd. announced the approval for its antibiotic, Miqnaf (Nafithromycin), by the Central Drugs Standard Control Organization (CDSCO), a fourth-generation macrolide for community-acquired bacterial pneumonia (CABP) in adults.

Key Insights

The report covers the following key insights:

• Key Industry Developments (Mergers, Acquisitions, and Partnerships)
• New Product Launches/Approvals, by Key Players
• Pipeline Analysis, By Key Players
• Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
• Impact of COVID-19 on the Market

Segmentation

Analysis by Drug 

By drug, the market is divided into erythromycin, azithromycin, clarithromycin, and others.

The azithromycin is expected to hold a significant market share in the coming years. It provides advantages over the previous generation of macrolides. It also provides antimicrobial properties against the broad-spectrum strains of pneumococcus. There has been a sudden rise in the prescriptions of azithromycin in many countries, contributing to its significant market share.

• For instance, in 2022, according to the data by ClinCalc, the estimated number of prescriptions in the U.S. for Azithromycin alone is 8,770,185 prescriptions, with the estimated number of patients nearly around 7,146,386.

Analysis by Indication

By indication, the market is divided into respiratory infections, skin infections, sexually transmitted diseases (STDs), and others.

The most prominent indication affecting the population is respiratory tract infections. The most prominent respiratory indications can be expressed as pneumonia, sinusitis, pharyngitis, tonsillitis, and diphtheria, with an increasing number of cases every year. The use of macrolides is recommended for most respiratory tract infections.

• For instance, in February 2024, the World Health Organization (WHO) released new guidelines for clinical management of diphtheria, a bacterial infection affecting the mucous membranes of the nose and throat, that recommend the use of macrolides as the first line of treatment.

Analysis by Route of Administration

By route of administration, the market is divided into oral and parenteral.

The oral segment is expected to hold a substantial share of the global market during the forecast period. Although macrolides can be administered both orally in the form of tablets as well as parenteral via injection, the oral tablets are easier to use and are available in all pharmacy retail stores. Thus, many pharmaceutical giants also emphasis the manufacture of oral tablets over injections. 

• For instance, in March 2023, Zydus Lifesciences Ltd. announced that it received final approval from the U.S. Food and Drug Administration (U.S. FDA) for Erythromycin Tablets USP, 250 mg and 500 mg, which is used to treat a wide variety of bacterial infections.

Analysis by Age Group

By age group, the market is divided into adults and pediatric.

The pediatric segment is expected to grow exponentially over the forecast period. Although a number of the macrolide antibiotics are approved for consumption by adults, a significant number of the macrolide antibiotics currently in use are prescribed for children.

• For instance, in January 2020, the U.S. FDA approved Merck’s DIFICID (fidaxomicin) for the treatment of Clostridioides difficile in children ages six months and older. DIFICID is a macrolide antibiotic indicated in adults and pediatric patients aged 6 months and older for the treatment of Clostridioides difficile. 

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The online pharmacies segment is projected to grow at the highest CAGR during the projection period. The growth of the segment is attributed to the increasing number of key pharmaceutical players entering into the online pharmacies space, along with the brick-and-mortar retail pharmacies, to increase the accessibility of macrolides.

• For instance, in October 2024, Amazon announced the opening of 20 new online pharmacies in 2025 in the U.S. that will allow same-day delivery of drugs to almost 45% of U.S. shoppers. This will further fuel the growth of the online distribution channel for macrolide antibiotics.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounts for the largest macrolide antibiotics market share. North America invests heavily in its research capabilities and actively provides funding opportunities for the development of novel macrolides. Due to the presence of several antibiotic-resistant strains, various pharmaceutical companies are launching generic macrolides to cope with the rising demand in the North American Market.

• For instance, in May 2021, Teva announced the launch of its generic Erythromycin Tablets USP, used to treat or prevent a variety of bacterial infections, in the U.S.

Europe is the second-largest market based on the demand for macrolides. The growth is attributed to the increasing demand for broad-spectrum antibiotics across the various countries in Europe. Various studies have reported the increased demand for macrolides in Europe.

• For instance, in November 2024, a publication called the Annual Epidemiological Report highlighted that there were large increases in the consumption of broad-spectrum and last-line antibiotics between the years 2019-2021.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region's growth can be attributed to the increasing life expectancy and better healthcare facilities in the developing countries. This may lead to an increase in the demand for macrolides, propelling the regional market growth. China and India are making significant strides in this market.

Key Players Covered

The global macrolide antibiotics market represents a fragmented competitive structure, with several companies offering macrolide antibiotics.

The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Crescent Pharma Ltd. (U.K.)
• Wellona Pharma (India)
• Zydus Group. (India)
• Merck & Co., Inc. (U.S.)
• Alkem (India)
• Azurity Pharmaceuticals, Inc. (U.S.)

Key Industry Developments

• In December 2024, the Indian Ministry of Chemicals and Fertilizers reported the development of Nafithromycin, which is ten times more effective than the current antibiotic treatments, under the funding by the Biotechnology Industry Research Assistance Council (BIRAC).
• In February 2022, Alembic Pharmaceuticals Limited received the final approval from the U.S. FDA for the company’s Abbreviated New Drug Application (ANDA) of Clarithromycin tablets USP, 250 mg and 500 mg.